Company news, research breakthroughs, and major announcements across industries.

Home/Science

Science |Prilenia and Ferrer

Prilenia and Ferrer Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease

Logo_PRILENIA_FERRER_CMYK_COLOR.jpg
Logo_PRILENIA_FERRER_CMYK_COLOR.jpg

Prilenia Therapeutics B.V. and Ferreri today announced that the confirmatory Phase 3 PRECISE-HD study of investigational pridopidine in Huntington's disease (HD) has received authorization to begin in participating EU Member States (clinicaltrialsregister.eu 2026-526093-16-00, clinicaltrials.gov NCT07609108). Recruitment in the EU is expected to commence this month, joining currently recruiting sites in the US and UK, wi...

  • PublishedOctober 22, 2026 · 4:34 AM
  • LocationNAARDEN, Netherlands & WALTHAM, Mass. & BARCELONA, Spain
  • IndustryScience
  • LanguageEN

Published by Business Wire. Read the original announcement for the full release.

Read the full announcement →

Latest from leading organizations

Explore recent announcements by organization